查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088972

自體免疫疾病體外診斷 (IVD) 和實驗室自建 (LDT) 市場：2026-2032 年全球市場預測（按產品類型、檢測類型、技術、檢體類型、應用、最終用戶和分銷管道分類）

IVD & LDT For Autoimmune Diseases Market by Product Type, Test Type, Technology, Sample Type, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，自體免疫疾病的體外診斷和實驗室自建檢測市場將成長至 298.5 億美元，複合年成長率為 7.15%。

主要市場統計數據
基準年 2025 184億美元
預計年份：2026年 196.9億美元
預測年份 2032 298.5億美元
複合年成長率 (%) 7.15%

自體免疫疾病的診斷取決於三個因素的交會：臨床需求高、診斷工具不斷擴展、法律規範加大。目前已知的自體免疫疾病超過80種，包括類風濕性關節炎、全身性紅斑性狼瘡、乳糜瀉、自體免疫甲狀腺疾病、發炎性腸道疾病和第1型糖尿病。診斷通常需要結合臨床評估、自體抗體檢測、發炎標記檢測、組織病理學檢查、影像學檢查，在某些情況下還需要分子和基因檢測。

體外診斷 (IVD) 和實驗室自建檢測 (LDT) 的生態系統在早期檢測、鑑別診斷、疾病分層和治療監測中發揮核心作用。自體免疫疾病的關鍵 IVD 類別包括抗核抗體檢測、可萃取核抗原譜、抗環瓜氨酸肽抗體檢測、抗雙股 DNA 抗體檢測、抗磷脂抗體組合、組織轉谷氨醯胺酶檢測、甲狀腺自體抗體檢測、補體檢測和多重免疫檢測。當罕見疾病的複雜性、低發病率適應症或快速變化的生物標記使得標準化商業試劑盒難以應用時，實驗室自建檢測 (LDT) 繼續為自體免疫疾病的特異性診斷提供支持。

人口老化、疾病意識增強、專科醫療服務覆蓋範圍擴大以及診斷延遲帶來的臨床影響，都進一步加劇了對自體免疫疾病檢測的需求。根據美國國立衛生研究院 (NIH) 估計，美國有超過 2,400 萬人患有自體免疫疾病，人口調查顯示，抗核抗體的盛行率呈上升趨勢。這些趨勢促使人們持續投資於自體免疫疾病檢測、品管系統、數位化檢查室基礎設施以及實證生物標記檢驗。

自體免疫診斷領域的變革性變化

自體免疫疾病的診斷領域正從以症狀為導向、針對單一分析物的檢測方法，轉向整合的、數據豐富的診斷流程。實驗室和製造商正在擴展其產品線，從傳統的間接螢光和酵素連結免疫吸附試驗（ELISA）擴展到化學冷光免疫檢測、線性免疫檢測、多重以微珠為基礎平台、微陣列和自動化工作流程系統。這些技術提高了處理能力、可重複性和基於檢測組合的診斷準確性，尤其是在抗核抗體（ANA）反射性檢測、類風濕性關節炎血清學檢測、乳糜瀉篩檢和自體免疫甲狀腺疾病檢測等高通量領域。

人工智慧對體外診斷和實驗室自建工作流程的累積影響

人工智慧正日益影響自體免疫相關體外診斷（IVD）和實驗室自建檢測（LDT）的工作流程，但其應用程度因地區而異，在結構化資料集、影像分析和基於規則的決策機制已較為成熟的地區，人工智慧的應用最為顯著。人工智慧驅動的模式識別可以輔助螢光（ANA）免疫螢光結果的判讀，從而降低判讀人員之間的差異，並提高高通量檢查室的工作流程效率。此外，結合自體抗體譜、發炎標記、人口統計資訊、症狀和時間序列實驗室數值的機器學習模型也正在評估中，以支持鑑別診斷和風險分層。

北美、歐洲、亞太和新興市場的關鍵區域洞察

北美地區憑藉其高昂的醫療保健支出、廣泛的專業實驗室資源、完善的醫保報銷機制以及眾多獲得CLIA認證的實驗室，仍然是自體免疫相關體外診斷試劑（IVD）和實驗室自建檢測（LDT）應用領域的領先地區。美國在LDT的研發、參考實驗室規模化以及數位化檢測申請創新方面處於領先地位，而加拿大則透過公共醫療保健計劃和省級實驗室網路支持LDT的應用。隨著FDA對許多LDT的監管日益規範化，該地區的合規性也發生了顯著變化。

對七國集團、歐盟、金磚國家、東協、海灣合作理事會和北約市場進行關鍵群體分析。

七國集團（G7）憑藉其先進的醫療基礎設施、健全的管理體制、高診斷利用率和成熟的報銷評估體系，在自體免疫診斷（IVD）創新領域發揮核心作用。美國、日本、德國、法國、義大利、加拿大和英國在檢測方法檢驗、臨床指南制定、自動化實施和實證醫學證據產生方面具有顯著影響力。這些國家的檢查室也是數位病理學、人工智慧驅動的觀察解讀、整合實驗室資訊系統和整合臨床決策支援系統的早期採用者。

主要自體免疫疾病體外診斷和實驗室自建市場的關鍵國家洞察

美國是自體免疫實驗室自建檢測（LDT）市場中最具影響力的國家，這得益於其大規模的參考實驗室體系、完善的臨床實驗室改進法案（CLIA）框架、專業的檢測人員隊伍以及對先進檢測方法的快速應用。美國食品藥物管理局（FDA）2024年發布的LDT最終規則為合規策略、檢驗投資以及實驗室與體外診斷（IVD）製造商之間的合作提供了新的方向。在加拿大，省級醫療保健系統和認證實驗室網路的需求穩定成長。同時，在墨西哥，自體免疫檢測正透過私人實驗室和都市區醫院網路不斷擴展。巴西憑藉其龐大的人口、完善的私人診斷基礎設施、三級醫療體係以及不斷擴大的免疫學檢測服務，在拉丁美洲處於領先地位。

為自體免疫診斷產業的領導者提供的實用建議

產業領導者應優先考慮證據產生、監管合規準備以及實現具有臨床意義的差異化。自體免疫檢測必須展現出分析表現、臨床有效性、可重複性以及在不同患者群體中清晰的解讀價值。各組織必須透過加強設計控制、驗證文件、品管系統、上市後監測和實際應用性能監測，為日益嚴格的監管要求做好準備。

自體免疫體外診斷和實驗室自建檢測分析的實證調查方法

本執行摘要是基於符合醫療保健市場情報標準的系統性二手調查方法。分析整合了來自監管機構、公共衛生機構、同行評審文獻、臨床實驗室標準、公開資訊以及認證醫療機構的資訊。主要參考領域包括美國食品藥物管理局 (FDA) 關於體外診斷 (IVD) 和實驗室自建檢測 (LDT) 的政策、歐盟體外醫療設備法規 (IVDR) 的實施、臨床實驗室改進法案 (CLIA) 下的檢查室監管、美國國立衛生研究院 (NIH) 關於自體免疫疾病的信息、基於人群的自身免疫指南以及基於自身免疫指南的自體免疫指南的生物標記的研究證據。

結論：證據、自動化和合規性將決定未來的成長。

自體免疫疾病的體外診斷（IVD）和實驗室自建檢測（LDT）市場正進入一個更主導實證醫學、技術更先進且監管日益嚴格的階段。不斷成長的臨床需求、公眾意識的提高以及自體免疫疾病診斷複雜性的增加，都推動了對精準自身抗體檢測、多重檢測、自動化免疫檢測和專業檢查室自建檢測（LDT）的持續需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：自體免疫疾病體外診斷與實驗室自建市場：依產品類型分類

  • 體外診斷
  • 實驗室自建檢測 (LDT)

第8章：自體免疫疾病體外診斷與實驗室自建市場：依檢測類型分類

  • 抗核抗體（ANA）檢測
    • 採用ELISA法進行ANA檢測
    • 採用IFA方法進行ANA檢測
  • 自體抗體檢測
    • 抗雙股DNA
    • 反中共
    • 抗ENA面板
  • 發炎標記檢測
    • CRP
    • ESR
  • 基因檢測
    • HLA型檢測
    • 基於SNP的檢測

第9章：自體免疫疾病體外診斷與實驗室自建市場：依技術分類

  • 免疫檢測
    • ELISA
    • CLIA
    • RIA
    • FIA
  • 分子診斷
    • PCR
    • NGS
    • 微陣列
  • 流式細胞技術
  • 螢光

第10章：自體免疫疾病體外診斷與實驗室自建市場：依檢體類型分類

  • 組織切片檢查
  • 唾液
  • 尿
  • 血
    • 血清
    • 電漿

第11章：自體免疫疾病的體外診斷與實驗室自建市場：按應用領域分類

  • 乳糜瀉
  • 多發性硬化症
  • 類風濕性關節炎
  • 全身性紅斑性狼瘡
  • 1型糖尿病

第12章：自體免疫疾病的體外診斷和實驗室自建市場：按最終用戶分類

  • 學術研究機構
  • 診斷檢查室
  • 醫院
    • 民眾
    • 私人的
  • 參考實驗室

第13章：自體免疫疾病體外診斷與實驗室自建市場：依通路分類

  • 離線
  • 線上

第14章：自體免疫疾病體外診斷與實驗室自建市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：自體免疫疾病體外診斷與實驗室自建市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：自體免疫疾病體外診斷與實驗室自建市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • A. Menarini Diagnostics srl
  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • AESKU.GROUP GmbH & Co. KG
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Corgenix, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • EUROIMMUN Medizinische Labordiagnostika AG
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd
  • Gold Standard Diagnostics
  • Grifols, SA
  • Hycor Biomedical LLC
  • Inova Diagnostics, Inc.
  • KRONUS
  • LabCorp
  • Myriad Genetics, Inc.
  • Omega Diagnostics Group plc
  • Quest Diagnostics Incorporated
  • QuidelOrtho Corporation
  • Revvity, Inc.
  • Sebia
  • Seramun Diagnostica GmbH
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Werfen SA
Product Code: MRR-ED54C46E8807

The IVD & LDT For Autoimmune Diseases Market is projected to grow by USD 29.85 billion at a CAGR of 7.15% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.40 billion
Estimated Year [2026] USD 19.69 billion
Forecast Year [2032] USD 29.85 billion
CAGR (%) 7.15%

Autoimmune disease diagnostics sit at the intersection of high clinical need, expanding test menus, and tightening regulatory oversight. More than 80 autoimmune diseases are recognized, including rheumatoid arthritis, systemic lupus erythematosus, celiac disease, autoimmune thyroid disease, inflammatory bowel disease, and type 1 diabetes. Diagnosis often requires a combination of clinical assessment, autoantibody testing, inflammatory markers, histopathology, imaging, and, in selected cases, molecular or genetic assays.

The IVD and LDT ecosystem is central to earlier detection, differential diagnosis, disease stratification, and therapy monitoring. Core autoimmune IVD categories include antinuclear antibody testing, extractable nuclear antigen panels, anti-CCP assays, anti-dsDNA testing, antiphospholipid antibody panels, tissue transglutaminase assays, thyroid autoantibodies, complement testing, and multiplex immunoassays. Laboratory-developed tests continue to support specialized autoimmune diagnostics where rare disease complexity, low-volume indications, or rapidly evolving biomarkers make standardized commercial kits less available.

Demand is reinforced by aging populations, improved disease awareness, wider access to specialist care, and the clinical consequences of delayed diagnosis. In the United States, the National Institutes of Health has cited autoimmune diseases as affecting more than 24 million people, while population studies have documented rising antinuclear antibody prevalence over time. These signals support sustained investment in autoimmune disease testing, quality systems, digital laboratory infrastructure, and evidence-based biomarker validation.

Transformative Shifts in the Autoimmune Diagnostics Landscape

The autoimmune diagnostics landscape is shifting from single-analyte, symptom-triggered testing toward integrated, data-rich diagnostic pathways. Laboratories and manufacturers are expanding from traditional indirect immunofluorescence and ELISA methods into chemiluminescence immunoassays, line immunoassays, multiplex bead-based platforms, microarrays, and automated workflow systems. These technologies improve throughput, reproducibility, and panel-based interpretation, especially in high-volume areas such as ANA reflex testing, rheumatoid arthritis serology, celiac disease screening, and autoimmune thyroid testing.

Regulatory transformation is one of the defining shifts. In the United States, the FDA issued its 2024 final rule to phase out the general enforcement discretion approach for many laboratory-developed tests, increasing the importance of analytical validity, clinical validity, quality management, and post-market oversight. In Europe, the In Vitro Diagnostic Regulation has raised evidence and conformity assessment expectations, particularly for higher-risk diagnostics and companion diagnostics. These reforms are pushing laboratories, IVD manufacturers, and health systems to strengthen documentation, validation, traceability, and clinical performance evidence.

Commercial models are also changing. Reference laboratories, hospital networks, and diagnostic manufacturers are moving toward integrated test utilization management, reflex algorithms, clinical decision support, and digital reporting. The result is a market where differentiation depends not only on assay sensitivity and specificity but also on turnaround time, interpretive clarity, reimbursement alignment, automation compatibility, and proven clinical utility.

Cumulative Impact of Artificial Intelligence on IVD and LDT Workflows

Artificial intelligence is increasingly influencing autoimmune IVD and LDT workflows, although adoption is uneven and strongest where structured datasets, image analysis, and rule-based interpretation already exist. AI-enabled pattern recognition can support ANA immunofluorescence interpretation, reduce inter-reader variability, and improve workflow efficiency in laboratories managing high test volumes. Machine learning models are also being evaluated for combining autoantibody profiles, inflammatory markers, demographics, symptoms, and longitudinal laboratory values to support differential diagnosis and risk stratification.

The cumulative impact of AI is most practical when it enhances, rather than replaces, validated diagnostic processes. In autoimmune testing, false positives and nonspecific autoantibody findings are common clinical challenges; AI can help by incorporating pretest probability, reflex testing rules, and evidence-based reporting logic. This can reduce unnecessary downstream testing and improve the consistency of recommendations across decentralized health systems.

AI adoption must remain anchored in regulatory-grade validation, bias assessment, cybersecurity, and clinical governance. The FDA maintains a public list of AI- and machine learning-enabled medical devices, demonstrating regulatory attention to software-driven diagnostics, while global authorities continue to refine expectations for transparency and lifecycle management. For autoimmune diagnostics, the near-term opportunity is operationally focused: faster image review, smarter reflex pathways, quality control monitoring, and improved physician-facing interpretation.

Key Regional Insights Across North America, Europe, Asia-Pacific, and Emerging Markets

North America remains a leading region for autoimmune IVD and LDT adoption due to high healthcare spending, broad access to specialty laboratories, established reimbursement structures, and a large base of CLIA-certified laboratories. The United States drives innovation in LDT development, reference laboratory scale, and digital test ordering, while Canada supports adoption through publicly funded healthcare systems and provincial laboratory networks. The region is also experiencing a major compliance shift as FDA oversight of many LDTs becomes more formalized.

Europe is shaped by strong clinical guidelines, advanced hospital laboratory infrastructure, and the implementation of the EU IVDR. Germany, France, Italy, Spain, and the Nordic countries are important markets for automated immunoassay systems, autoimmune panels, and standardized laboratory quality frameworks. The United Kingdom, while outside the European Union, continues to be influential through NHS procurement, health technology assessment, and centralized diagnostic initiatives.

Asia-Pacific is one of the fastest-evolving regions for autoimmune disease diagnostics, supported by large patient populations, expanding private healthcare, increasing specialist access, and investment in laboratory automation. China, Japan, India, South Korea, and Australia represent distinct growth pathways, ranging from high-volume hospital testing and domestic IVD manufacturing to advanced reference laboratory networks. Latin America, led by Brazil and Mexico, is expanding access to autoimmune testing through private laboratories and tertiary care centers, although reimbursement variability and uneven specialist distribution remain constraints. The Middle East is investing in advanced diagnostic infrastructure through GCC healthcare modernization programs, particularly in hospital automation and reference laboratory development. Africa remains earlier in adoption, with opportunities centered on laboratory capacity building, affordable assays, workforce training, and regional reference testing models that improve access beyond major urban centers.

Key Group Insights for G7, EU, BRICS, ASEAN, GCC, and NATO Markets

The G7 economies play a central role in autoimmune IVD innovation because they combine advanced healthcare infrastructure, strong regulatory systems, high diagnostic utilization, and mature reimbursement assessment. The United States, Japan, Germany, France, Italy, Canada, and the United Kingdom are influential in assay validation, clinical guideline development, automation adoption, and evidence generation. Their laboratories are also among the earliest adopters of digital pathology, AI-assisted interpretation, laboratory information system connectivity, and integrated clinical decision support.

The European Union is a pivotal group because the IVDR has changed market access requirements for IVD manufacturers and clinical laboratories serving EU member states. Stronger clinical evidence, post-market surveillance, and notified body involvement are reshaping product portfolios and encouraging a focus on well-validated autoimmune assays. NATO countries overlap significantly with North American and European markets, creating common demand for resilient supply chains, cybersecurity, standardized laboratory readiness, and continuity of diagnostic services across civilian and defense-linked health systems.

BRICS countries represent scale and long-term demand expansion, particularly through China, India, and Brazil, while Russia and South Africa add regional diagnostic capacity and localized healthcare priorities. These markets are expanding laboratory networks, domestic IVD production, and access to specialist diagnostics, although affordability and regional disparities remain important. ASEAN is gaining relevance as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines invest in private healthcare, medical tourism, public laboratory modernization, and specialty care access. The GCC is advancing through high-spending healthcare systems in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman, where premium diagnostics, hospital automation, reference laboratory partnerships, and national health transformation programs are increasingly important.

Key Country Insights for Major Autoimmune IVD and LDT Markets

The United States is the most influential country market for autoimmune LDTs because of its large reference laboratory sector, CLIA framework, specialist physician base, and rapid adoption of advanced assays. FDA's 2024 LDT final rule is reshaping compliance strategies, validation investments, and partnerships between laboratories and IVD manufacturers. Canada shows steady demand through provincial health systems and accredited laboratory networks, while Mexico is expanding autoimmune testing through private laboratories and urban hospital networks. Brazil leads Latin America with a large population, established private diagnostics infrastructure, tertiary care capacity, and growing access to immunology testing.

In Europe, Germany benefits from advanced laboratory automation, strong hospital infrastructure, and a major diagnostics manufacturing base. France, Italy, and Spain show sustained demand for autoimmune serology across rheumatology, gastroenterology, endocrinology, dermatology, neurology, and nephrology pathways. The United Kingdom remains important through NHS laboratory networks, health technology assessment, and centralized procurement models. Russia has domestic diagnostic capacity and demand for autoimmune testing, but international supply dynamics, localization requirements, and regulatory complexity can influence access to advanced platforms.

In Asia-Pacific, China combines large testing volumes, expanding hospital infrastructure, domestic IVD manufacturing scale, and policy support for local medical technology capability. India is growing through private diagnostic chains, rising specialist access, expanding urban healthcare networks, and increasing autoimmune disease awareness, although affordability and geographic variation remain challenges. Japan and South Korea are mature, technology-forward markets with high laboratory quality expectations, strong automation adoption, and advanced hospital-based diagnostic pathways. Australia supports advanced autoimmune diagnostics through public-private laboratory networks, specialist care pathways, national quality assurance practices, and broad use of standardized laboratory accreditation systems.

Actionable Recommendations for Autoimmune Diagnostics Industry Leaders

Industry leaders should prioritize evidence generation, regulatory readiness, and clinically meaningful differentiation. Autoimmune assays must demonstrate analytical performance, clinical validity, reproducibility, and clear interpretive value across diverse patient populations. Organizations should prepare for more demanding regulatory expectations by strengthening design controls, validation documentation, quality management systems, post-market surveillance, and real-world performance monitoring.

Commercial success will depend on workflow integration. Manufacturers and laboratories should develop autoimmune testing solutions that support reflex algorithms, automated sample handling, laboratory information system connectivity, digital result interpretation, and clinician-friendly reporting. In high-volume segments, automation and turnaround time can be decisive; in rare or complex autoimmune diseases, scientific credibility and specialist interpretation are more important.

Research Methodology for Evidence-Based Autoimmune IVD and LDT Analysis

This executive summary is built on a structured secondary research methodology aligned with healthcare market intelligence standards. The analysis synthesizes information from regulatory agencies, public health institutions, peer-reviewed literature, clinical laboratory standards, public disclosures, and recognized healthcare organizations. Key reference areas include FDA IVD and LDT policy, EU IVDR implementation, CLIA laboratory oversight, NIH autoimmune disease information, population-based autoantibody studies, clinical practice guidelines, and published evidence on autoimmune biomarker testing.

The research approach emphasizes triangulation across regulatory, clinical, technological, and commercial signals. Market direction is assessed by reviewing diagnostic platform evolution, laboratory automation trends, test utilization patterns, reimbursement considerations, and regional healthcare infrastructure. Country and regional insights are interpreted through healthcare access, laboratory capacity, regulatory maturity, disease awareness, specialist availability, and adoption of advanced immunoassay and molecular diagnostic technologies.

No unsupported market sizing claims are used in this summary. All conclusions are framed around verifiable industry drivers, documented regulatory changes, recognized clinical needs, and observable technology trends affecting autoimmune IVDs and laboratory-developed tests.

Conclusion: Evidence, Automation, and Compliance Define Future Growth

The IVD and LDT market for autoimmune diseases is entering a more evidence-driven, technology-enabled, and regulated phase. Rising clinical demand, improved awareness, and the complexity of autoimmune diagnosis are supporting continued need for accurate autoantibody testing, multiplex panels, automated immunoassays, and specialized laboratory-developed tests.

The strongest opportunities will favor organizations that combine scientific validity with operational excellence. Regulatory changes in the United States and Europe are raising expectations, while Asia-Pacific, Latin America, the Middle East, and Africa are expanding diagnostic access at different speeds. AI will add value where it improves reproducibility, workflow efficiency, and clinical interpretation within validated laboratory systems.

For industry leaders, the strategic priority is clear: build trustworthy autoimmune diagnostics that are clinically useful, scalable, compliant, and integrated into real-world care pathways. Organizations that align innovation with evidence, quality, and physician decision-making will be best positioned to compete in the evolving autoimmune disease diagnostics market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. IVD & LDT For Autoimmune Diseases Market, by Product Type

  • 7.1. In Vitro Diagnostic
  • 7.2. Lab Developed Test

8. IVD & LDT For Autoimmune Diseases Market, by Test Type

  • 8.1. Antinuclear Antibody (ANA) Tests
    • 8.1.1. ELISA-based ANA
    • 8.1.2. IFA-based ANA
  • 8.2. Autoantibody Tests
    • 8.2.1. Anti-dsDNA
    • 8.2.2. Anti-CCP
    • 8.2.3. Anti-ENA Panel
  • 8.3. Inflammatory Marker Tests
    • 8.3.1. CRP
    • 8.3.2. ESR
  • 8.4. Genetic Tests
    • 8.4.1. HLA Typing
    • 8.4.2. SNP-based Testing

9. IVD & LDT For Autoimmune Diseases Market, by Technology

  • 9.1. Immunoassay
    • 9.1.1. ELISA
    • 9.1.2. CLIA
    • 9.1.3. RIA
    • 9.1.4. FIA
  • 9.2. Molecular Diagnostics
    • 9.2.1. PCR
    • 9.2.2. NGS
    • 9.2.3. Microarrays
  • 9.3. Flow Cytometry
  • 9.4. Immunofluorescence

10. IVD & LDT For Autoimmune Diseases Market, by Sample Type

  • 10.1. Tissue Biopsies
  • 10.2. Saliva
  • 10.3. Urine
  • 10.4. Blood
    • 10.4.1. Serum
    • 10.4.2. Plasma

11. IVD & LDT For Autoimmune Diseases Market, by Application

  • 11.1. Celiac Disease
  • 11.2. Multiple Sclerosis
  • 11.3. Rheumatoid Arthritis
  • 11.4. Systemic Lupus Erythematosus
  • 11.5. Type 1 Diabetes

12. IVD & LDT For Autoimmune Diseases Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospital
    • 12.3.1. Public
    • 12.3.2. Private
  • 12.4. Reference Laboratories

13. IVD & LDT For Autoimmune Diseases Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. IVD & LDT For Autoimmune Diseases Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. IVD & LDT For Autoimmune Diseases Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. IVD & LDT For Autoimmune Diseases Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. A. Menarini Diagnostics s.r.l.
  • 18.2. Abbott Laboratories
  • 18.3. Adaptive Biotechnologies Corporation
  • 18.4. AESKU.GROUP GmbH & Co. KG
  • 18.5. Agilent Technologies, Inc.
  • 18.6. Bio-Rad Laboratories, Inc.
  • 18.7. bioMerieux S.A.
  • 18.8. Corgenix, Inc.
  • 18.9. Danaher Corporation
  • 18.10. DiaSorin S.p.A.
  • 18.11. EUROIMMUN Medizinische Labordiagnostika AG
  • 18.12. Exagen Inc.
  • 18.13. F. Hoffmann-La Roche Ltd
  • 18.14. Gold Standard Diagnostics
  • 18.15. Grifols, S.A.
  • 18.16. Hycor Biomedical LLC
  • 18.17. Inova Diagnostics, Inc.
  • 18.18. KRONUS
  • 18.19. LabCorp
  • 18.20. Myriad Genetics, Inc.
  • 18.21. Omega Diagnostics Group plc
  • 18.22. Quest Diagnostics Incorporated
  • 18.23. QuidelOrtho Corporation
  • 18.24. Revvity, Inc.
  • 18.25. Sebia
  • 18.26. Seramun Diagnostica GmbH
  • 18.27. Siemens Healthineers AG
  • 18.28. Thermo Fisher Scientific Inc.
  • 18.29. Werfen S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IN VITRO DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IN VITRO DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IN VITRO DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LAB DEVELOPED TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LAB DEVELOPED TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LAB DEVELOPED TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTINUCLEAR ANTIBODY (ANA) TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTINUCLEAR ANTIBODY (ANA) TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTINUCLEAR ANTIBODY (ANA) TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ELISA-BASED ANA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ELISA-BASED ANA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ELISA-BASED ANA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IFA-BASED ANA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IFA-BASED ANA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IFA-BASED ANA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOANTIBODY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOANTIBODY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOANTIBODY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-DSDNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-DSDNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-DSDNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-CCP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-CCP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-CCP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-ENA PANEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-ENA PANEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-ENA PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFLAMMATORY MARKER TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFLAMMATORY MARKER TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLAMMATORY MARKER TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CRP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CRP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ESR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ESR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ESR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENETIC TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENETIC TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENETIC TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HLA TYPING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HLA TYPING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HLA TYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SNP-BASED TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SNP-BASED TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SNP-BASED TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CLIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CLIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CLIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MICROARRAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MICROARRAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MICROARRAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNOFLUORESCENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNOFLUORESCENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNOFLUORESCENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TISSUE BIOPSIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TISSUE BIOPSIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TISSUE BIOPSIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELIAC DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CELIAC DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELIAC DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PUBLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PUBLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PUBLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PRIVATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PRIVATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PRIVATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
  • TABLE 262. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 263. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 264. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 265. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 267. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 268. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 270. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 273. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 305. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 306. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
  • TABLE 310. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 311. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 312. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 313. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 315. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 316. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 318. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 319. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 320. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 321. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
  • TABLE 326. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
  • TABLE 327. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 328. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
  • TABLE 329. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 330. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 331. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 332. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 334. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 335. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 336. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 337. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 338. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 340. UNITE